ResMed
Builds connected sleep-apnea devices, masks, ventilators, and home-care software.
Something off on this page? Send us feedback.
Profile
Sells connected positive airway pressure devices, masks, home ventilators, diagnostics, and care-management software, with most revenue coming from sleep and breathing devices and recurring accessories. Cloud monitoring links patients and providers, while reimbursement, medical-device regulation, and component supply shape the business.
Designs and sells positive airway pressure devices, masks, accessories, home ventilators, diagnostics, and connected software for sleep apnea and other respiratory disorders. The Sleep and Breathing Health segment includes AirSense and AirCurve therapy devices, AirFit and AirTouch masks, AirView clinician monitoring, and myAir patient support, sold in more than 140 countries.
Connects therapy hardware to remote monitoring, settings changes, troubleshooting, and patient coaching. Residential Care Software provides Brightree and MEDIFOX DAN workflow systems to home-medical-equipment and residential care providers; MatrixCare remains in the segment pending its agreed sale.
Sells primarily through home-medical-equipment providers, distributors, sleep clinics, and health systems. Demand depends on medical-device approvals, quality compliance, and third-party reimbursement, while some configured device components come from single-source suppliers.
Company facts
Categories
Key statistics
Year to date −1.8% · Average volume (30d) 1.4M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Redburn Partners | Target | $230 | |||
| Aug 7, 2026 | Robert W. Baird | Target | $225 | $213 | ||
| Aug 7, 2026 | Keybanc | Reiterate | Overweight | $266 | $255 | |
| Jul 21, 2026 | UBS | Reiterate | Buy | $345 | $300 | |
| Jul 16, 2026 | RBC Capital | Downgrade | Outperform | Sector Perform | $276 | $234 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q4 FY26 | $2.89 | $2.95 | +2.1% | $1.46B | $1.46B | +0.2% | −5.06% |
| Apr 30, 2026Q3 FY26 | $2.80 | $2.86 | +2.1% | $1.42B | $1.43B | +0.8% | −4.11% |
| Jan 29, 2026Q2 FY26 | $2.74 | $2.81 | +2.6% | $1.40B | $1.42B | +1.6% | +0.27% |
| Oct 30, 2025Q1 FY26 | $2.51 | $2.55 | +1.6% | $1.33B | $1.34B | +0.2% | −2.13% |
Financial highlights
| 12 quarters | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.29B | $1.35B | $1.34B | $1.42B | $1.43B | $1.46B | |
| Gross profit | $766.4M | $820.1M | $820.8M | $884.7M | $891.0M | $861.2M | |
| Operating income | $426.3M | $454.5M | $446.5M | $497.6M | $499.8M | $448.7M | |
| Net income | $365.0M | $379.7M | $348.5M | $392.6M | $398.7M | $383.4M | |
| Diluted EPS | $2.48 | $2.58 | $2.37 | $2.68 | $2.71 | $2.64 | |
| Gross margin | 59.3% | 60.8% | 61.5% | 62.2% | 62.2% | 58.8% | |
| Operating margin | 33.0% | 33.7% | 33.4% | 35.0% | 34.9% | 30.7% |
Fiscal years (4-quarter sums)FY22 $3.58B · FY23 $4.22B · FY24 $4.69B · FY25 $5.15B · FY26 $5.65B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.47B · Total debt $825.9M · Total assets $8.97B · Shareholders' equity $6.59B
Dividends
Raised for 12 straight years — most recently to $0.66 from $0.60 in Aug 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 20, 2026 | Aug 20 | Sep 24 | $0.66 | raised from $0.60 |
| May 14, 2026 | May 14 | Jun 18 | $0.60 | |
| Feb 12, 2026 | Feb 12 | Mar 19 | $0.60 | |
| Nov 13, 2025 | Nov 13 | Dec 18 | $0.60 | |
| Aug 14, 2025 | Aug 14 | Sep 18 | $0.60 | raised from $0.53 |
| May 8, 2025 | May 8 | Jun 12 | $0.53 | |
| Feb 13, 2025 | Feb 13 | Mar 20 | $0.53 | |
| Nov 7, 2024 | Nov 7 | Dec 12 | $0.53 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 145.06M · Float 144.16M · 99.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 12.32M | 8.49% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 9.47M | 6.53% | 13F | Aug 13, 2026 |
| AustralianSuper Pty Ltd | 8.28M | 5.70% | 13G | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 7.91M | 5.46% | 13F | Aug 13, 2026 |
| State Street Corp | 6.68M | 4.61% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 7, 2026 | Michael J. Farrell | director, officer: Chairman and CEO | −4,991 | $205.69 |
| Aug 5, 2026 | Peter C. Farrell | director | −8,000 | $225.00 |
| Jul 7, 2026 | Michael J. Farrell | director, officer: Chairman and CEO | −4,991 | $218.55 |
| Jun 8, 2026 | Michael J. Farrell | director, officer: Chairman and CEO | −4,991 | $193.96 |
| May 7, 2026 | Michael J. Farrell | director, officer: Chairman and CEO | −4,991 | $207.82 |
Peers
- Philips (ADR)
Primary device rival globally; US new-device sales blocked by FDA consent decree.
- Five Point
Named primary rival in OSA masks and hospital respiratory; $2B+ FY2025 revenue.
- Inspire Medical Systems
Implantable nerve stimulator for CPAP-intolerant OSA patients; $912M FY2025.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ResMed | $240.33 | +0.01% | $34.86B | 23.1 | 19.8 | 6.2 | +8.6% |
| Philips (ADR) | $26.72 | +0.06% | $26.12B | 19.9 | 13.7 | 1.3 | −2.9% |
| Five Point | $5.11 | −0.10% | $363.3M | 14.7 | — | 3.1 | +86.0% |
| Inspire Medical Systems | $61.44 | −0.11% | $1.78B | 13.3 | 47.3 | 2.0 | −7.6% |
| Median | 14.7 | 30.5 | 2.0 | −2.9% |